Related Experiment Video
Updated: Apr 21, 2026
08:29
An Open Source Technology Platform to Manufacture Hydrogel-Based 3D Culture Models in an Automated and Standardized Fashion
Published on: March 31, 2022
5.0K
Controversies in ASSAY and drug development technologies: a focus on assessing irreproducibility
J Fraser Glickman1, Thomas Lundbäck, Andrew D Napper
11 The Rockefeller University , New York, New York.
Assay and Drug Development Technologies
|November 11, 2014
Summary
Scientific irreproducibility is a growing concern, amplified by technology and high expectations. Editorial board members shared insights on this complex issue, highlighting areas for improvement in scientific discovery and drug development.
Area of Science:
- Biomedical Research
- Drug Discovery and Development
- Scientific Methodology
Background:
- The impact of scientific irreproducibility on drug discovery is a growing concern.
- This issue may be exacerbated by increased reliance on advanced technologies and unrealistic expectations in science.
- Understanding the root causes of irreproducibility is complex due to science's dependence on external forces.
Purpose of the Study:
- To gather expert opinions on the multifaceted problem of scientific irreproducibility.
- To explore the depth of the irreproducibility issue within the scientific community.
- To identify potential areas for improvement in scientific practices.
Main Methods:
- A series of questions were posed to members of an editorial board.
- Participants provided their perspectives on scientific irreproducibility.
- Responses were collected from various levels of expertise to gauge the problem's scope.
Main Results:
- Editorial board members offered diverse insights into scientific irreproducibility.
- The varied responses indicate the complexity and multi-layered nature of the problem.
- Participants highlighted different starting points for addressing and improving scientific rigor.
Conclusions:
- Scientific irreproducibility is a significant challenge with complex origins.
- Expert opinions suggest a need for targeted interventions to enhance scientific reliability.
- Addressing irreproducibility requires a comprehensive understanding of its impact on scientific advancement.
More Related Videos
Related Concept Videos
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
587
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
587
01:10In Vitro Drug Release Testing: Overview, Development and Validation
574
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
574
01:19Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence
229
Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
229
01:29Clinically Relevant Drug Product Specifications: Methods of Establishment
286
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
286
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
251
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
251
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
227
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
227